ALK and non-small cell lung carcinoma: ALK TKI are established first-line treatment options in advanced ALK rearranged NSCLC, with several next-generation ALK TKIs (alectinib [5,6], brigatinib [7], ensartinib [8] and lorlatinib [9]) demonstrating survival benefit compared with the first-generation ALK TKI crizotinib in phase III randomized controlled trials.